Nasdaq

QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch

Enabling highly automated screening solution for latent tuberculosis in all throughput segments Embedding QuantiFERON assays in the broad assay menu of DiaSorin’s LIAISON analyzers also gives current ...
Business Wire

QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early ...

HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the launch of the LIAISON ® LymeDetect ® Assay ...
Nasdaq

QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early ...

The LIAISON® LymeDetect® assay is a solution for the early diagnosis of Lyme Borreliosis combining detection of IgG and IgM Antibodies and cellular immunity The test is available in countries ...